The combined company will use RNA-based tools to enhance drug development by identifying the right patients for oncology drugs and potentially improving drug response rates.
The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.
In addition to the $24 million jury verdict, 10x must pay an additional $8.3 million in damages and $2.2 million in interest. It has appealed the case.
The company hopes to convert biopharma customers to increasingly comprehensive approaches, and intends to branch out further with blood-based exome sequencing next year.
